Related Experiment Videos
Patent ductus arteriosus in premature infants: a review of current management
Insights
Patent ductus arteriosus is a common heart defect in premature infants. Early aggressive therapy, including indomethacin, is recommended for closure, though effectiveness varies.
Area of Science:
- Neonatal cardiology
- Pediatric cardiovascular research
Background:
- Patent ductus arteriosus (PDA) is a frequent cardiac defect encountered by pediatricians.
- Increased awareness of prematurity issues led to a threefold rise in reported PDA frequency from 1970-1975.
Purpose of the Study:
- To review the challenges and therapeutic approaches for patent ductus arteriosus in neonates.
- To highlight the importance of early intervention in premature infants.
Main Methods:
- Review of clinical data and therapeutic outcomes for patent ductus arteriosus.
- Analysis of treatment strategies, including pharmacologic closure.
Main Results:
- Aggressive therapy for PDA closure is indicated within the first week of life for very immature infants.
- Pharmacologic closure using indomethacin demonstrates approximately 50% effectiveness.
Conclusions:
- Patent ductus arteriosus requires prompt attention in neonatal care.
- Indomethacin offers a viable, though not universally successful, option for PDA pharmacologic closure.
Abstract:
Problems related to the ductus arteriosus confront the pediatrician more than any other isolated cardiac defect. Due to increased awareness of the problems of prematurity, the reported frequency of patent ductus arteriosus increased threefold between 1970 and 1975. Aggressive therapy directed toward closure of the ductus is indicated within the first week of life in the very immature infant. Pharmacologic closure of the PDA with indomethacin is effective about half the time.